[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338686-105":59,"doc-detail-338686-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-n-methyl-lysine-histone-demethylase-kdm4-in-cancer-natural-products-inhibitors-as-a-driving-force-for-epigenetic-drug-discovery","Targeting N-Methyl-lysine Histone Demethylase KDM4 in Cancer - Natural Products Inhibitors as a Driving Force for Epigenetic Drug Discovery","","Reviewing KDM4A-F histone demethylase enzymes, this article links altered KDM4 expression or regulation to chromatin remodeling, transcriptional dysfunction, and aggressive cancer phenotypes. It summarizes medicinal chemistry efforts to discover KDM4 inhibitors, highlighting common pan-KDM4 activity with limited selectivity against other Jumonji members, frequent reliance on iron-chelating pharmacophores, and emerging evidence that non-chelating scaffolds can still inhibit KDM4. Natural products with monovalent or bivalent chelators show micromolar potency, supporting their use as templates for more potent and selective epigenetic therapeutics.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-n-methyl-lysine-histone-demethylase-kdm4-in-cancer-natural-products-inhibitors-as-a-driving-force-for-epigenetic-drug-discovery/338686/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-n-methyl-lysine-histone-demethylase-kdm4-in-cancer-natural-products-inhibitors-as-a-driving-force-for-epigenetic-drug-discovery/338686.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does KDM4 play in cancer biology?","Question",{"text":112,"@type":113},"KDM4 enzymes regulate histone methylation, and their overexpression or dysregulation is associated with cancers by altering chromatin structure and causing transcriptional dysfunction.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are iron-chelating features common in KDM4 inhibitors?",{"text":117,"@type":113},"KDM4 catalytic activity uses Fe(II) and 2-oxoglutarate, so many inhibitors include chelating groups that can coordinate the catalytic iron in the active site.",{"name":119,"@type":110,"acceptedAnswer":120},"How do natural products contribute to KDM4 inhibitor development?",{"text":121,"@type":113},"Natural products containing mono- or bivalent chelators have been identified as KDM4 inhibitors with micromolar potency, suggesting they can serve as templates for designing more potent and selective derivatives.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338686,1790067575,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","ChemMedChem  \nReview  \n[doi.org/10.1002/cmdc.202400682](doi.org/10.1002/cmdc.202400682)  \n[www.chemmedchem.org](www.chemmedchem.org)  \nTargeting N-Methyl-lysine Histone Demethylase KDM4 in Cancer: Natural Products Inhibitors as a Driving Force for Epigenetic Drug Discovery  \nIlaria Cursaro,[a] Leonardo Milioni,[a] Kourosh Eslami,[b] Hajar Sirous,[b] Gabriele Carullo,*[a] Sandra Gemma,[a] Stefania Butini,[a] and Giuseppe Campiani[a]  \nChemMedChem 2025, 20, e202400682 (1 of 22) © 2024 The Authors. ChemMedChem published by Wiley-VCH GmbH  \nChemMedChem  \nReview  \n[doi.org/10.1002/cmdc.202400682](doi.org/10.1002/cmdc.202400682)  \n| KDM4A-F enzymes are a subfamily of histone demethylases containing the Jumonji C domain (JmjC) using Fe(II) and 2-oxoglutarate for their catalytic function. Overexpression orderegulation of KDM4 enzymes is associated with various cancers, altering chromatin structure and causing transcriptional dysfunction. As KDM4 enzymes have been associated with malignancy, they may represent novel targets for developing innovative therapeutic tools to treat different solid and blood tumors. KDM4A is the isozyme most frequently associated with aggressive phenotypes of these tumors. To this aim, industrial and academic medicinal chemistry efforts have identified different KDM4 inhibitors. Industrial and academic efforts in medicinal chemistry have identified numerous KDM4\u003Cbr>inhibitors, primarily pan-KDM4 inhibitors, though they often lack selectivity against other Jumonji family members. The pharmacophoric features of the inhibitors frequently include achelating group capable of coordinating the catalytic iron within the active site of the KDM4 enzyme. Nonetheless, nonchelating compounds have also demonstrated promising inhibitory activity, suggesting potential flexibility in the drug design. Several natural products, containing monovalent or bivalent chelators, have been identified as KDM4 inhibitors, albeit with a micromolar inhibition potency. This highlights the potential for leveraging them as templates for the design and synthesis of new derivatives, exploiting nature’s chemical diversity to pursue more potent and selective KDM4 inhibitors. |  |\n| --- | --- |\n| 1. Introduction\u003Cbr>Cancer is one of the most significant global public health concerns, as it currently claims millions of lives annually and continues to surge in prevalence. According to the World Health Organization (WHO), cancer ranks as the second leading cause of death worldwide, claiming around 10 million lives annually. Projections suggest a 63 % increase by 2040 compared to 2020, potentially reaching 16.3 million deaths. [1] Urgent action in prevention, early detection, and treatment is crucial to address the escalating threat of cancer, with advancements in anticancer drug discovery playing a pivotal role in expanding treatment options, enhancing survival rates, and ultimately transforming the landscape of cancer care. [2] Genetics and epigenetics intertwine to drive cancer development, as genetic mutations provide the initial triggers, while epigenetic modifications influence gene transcription patterns and expression of oncogenes and tumor suppressors, collectively shaping the malignancy progression.[3]\u003Cbr>It is known that in eukaryotic cells, the genetic material is intricately packaged within the nucleus by histone proteins, enabling the necessary compaction of DNA molecules to fit within the confined nuclear space. Central to this packaging mechanism is the nucleosome, the fundamental unit of chromatin structure. Each nucleosome comprises an octamer of histone proteins, specifically two copies each of H2A, H2B, H3 and H4 . Around this histone octamer, a 146-base pair segment of the DNA helix is wrapped. Every histone features a globular domain forming the core of the nucleosome, and an unstructured N-terminus. This N-terminal tail is a site for extensive\u003Cbr>[a] I. Cursaro, L. Milioni, G. Carullo, S. Gemma, S. Butini, G. Campiani Department ","cbCaisIzkouHqE1l","https://ap.wps.com/l/cbCaisIzkouHqE1l","pdf",4286712,22,"English","# Introduction\n## KDM4 enzymes and cancer link\n## Histones, nucleosomes, and epigenetic regulation\n## Strategies for KDM4 inhibition\n## Natural products as inhibitor templates","[{\"question\":\"What role does KDM4 play in cancer biology?\",\"answer\":\"KDM4 enzymes regulate histone methylation, and their overexpression or dysregulation is associated with cancers by altering chromatin structure and causing transcriptional dysfunction.\"},{\"question\":\"Why are iron-chelating features common in KDM4 inhibitors?\",\"answer\":\"KDM4 catalytic activity uses Fe(II) and 2-oxoglutarate, so many inhibitors include chelating groups that can coordinate the catalytic iron in the active site.\"},{\"question\":\"How do natural products contribute to KDM4 inhibitor development?\",\"answer\":\"Natural products containing mono- or bivalent chelators have been identified as KDM4 inhibitors with micromolar potency, suggesting they can serve as templates for designing more potent and selective derivatives.\"}]","Targeting N-Methyl-lysine Histone Demethylase KDM4 in Cancer - Natural Products Inhibitors as a Driving Force for Epigenetic Drug Discovery | PDF",1790025067,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b84b2e70539564ab87414f60e5a24b79.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a27db5249af00ecebe676c1458657645.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c24c411574f318acaadffbd36ce546b6.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/630e77aaf622da2675ef9cf114b0f828.webp",980,1385]